ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Opioid Antagonist Market Research Report 2025
Published Date: July 2025
|
Report Code: QYRE-Auto-16O7647
Home | Market Reports | Health| Pharmacy| Drugs & Medications
Global Opioid Antagonist Market Insights Forecast to 2028
BUY CHAPTERS

Global Opioid Antagonist Market Research Report 2025

Code: QYRE-Auto-16O7647
Report
July 2025
Pages:97
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Alkermes plc
Titan pharmaceuticals
Opiant Pharmaceuticals
Hikma Pharmaceuticals
Orexo
Camurus AB
Acura Pharmaceuticals
Shionogi
BioDelivery Sciences International
Collegium Pharmaceutical
Astrazeneca plc

Opioid Antagonist Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Opioid Antagonist Market

Opioid Antagonist Market

The global market for Opioid Antagonist was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Opioid Antagonist, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Opioid Antagonist.
The Opioid Antagonist market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Opioid Antagonist market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Opioid Antagonist manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Opioid Antagonist Market Report

Report Metric Details
Report Name Opioid Antagonist Market
CAGR 5%
Segment by Type
Segment by Application
  • Hospitals
  • Clinics
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Indivior, Alkermes, Titan Pharmaceuticals, Opiant Pharmaceuticals, Hikma Pharmaceuticals, Orexo, Camurus, Acura Pharmaceuticals, Shionogi, BioDelivery Sciences International, Collegium Pharmaceutical, AstraZeneca
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Opioid Antagonist manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Opioid Antagonist in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Opioid Antagonist Market report?

Ans: The main players in the Opioid Antagonist Market are Indivior, Alkermes, Titan Pharmaceuticals, Opiant Pharmaceuticals, Hikma Pharmaceuticals, Orexo, Camurus, Acura Pharmaceuticals, Shionogi, BioDelivery Sciences International, Collegium Pharmaceutical, AstraZeneca

What are the Application segmentation covered in the Opioid Antagonist Market report?

Ans: The Applications covered in the Opioid Antagonist Market report are Hospitals, Clinics, Others

What are the Type segmentation covered in the Opioid Antagonist Market report?

Ans: The Types covered in the Opioid Antagonist Market report are Oral, Parenteral

Recommended Reports

Pain Relief Markets

Drug Delivery Devices

Therapeutic Pharmaceuticals

1 Opioid Antagonist Market Overview
1.1 Product Definition
1.2 Opioid Antagonist by Type
1.2.1 Global Opioid Antagonist Market Value Comparison by Type (2024 VS 2031)
1.2.2 Oral
1.2.3 Parenteral
1.3 Opioid Antagonist by Application
1.3.1 Global Opioid Antagonist Market Value by Application (2024 VS 2031)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Opioid Antagonist Market Size Estimates and Forecasts
1.4.1 Global Opioid Antagonist Revenue 2020-2031
1.4.2 Global Opioid Antagonist Sales 2020-2031
1.4.3 Global Opioid Antagonist Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Opioid Antagonist Market Competition by Manufacturers
2.1 Global Opioid Antagonist Sales Market Share by Manufacturers (2020-2025)
2.2 Global Opioid Antagonist Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Opioid Antagonist Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Opioid Antagonist, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Opioid Antagonist, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Opioid Antagonist, Product Type & Application
2.7 Global Key Manufacturers of Opioid Antagonist, Date of Enter into This Industry
2.8 Global Opioid Antagonist Market Competitive Situation and Trends
2.8.1 Global Opioid Antagonist Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Opioid Antagonist Players Market Share by Revenue
2.8.3 Global Opioid Antagonist Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Opioid Antagonist Market Scenario by Region
3.1 Global Opioid Antagonist Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Opioid Antagonist Sales by Region: 2020-2031
3.2.1 Global Opioid Antagonist Sales by Region: 2020-2025
3.2.2 Global Opioid Antagonist Sales by Region: 2026-2031
3.3 Global Opioid Antagonist Revenue by Region: 2020-2031
3.3.1 Global Opioid Antagonist Revenue by Region: 2020-2025
3.3.2 Global Opioid Antagonist Revenue by Region: 2026-2031
3.4 North America Opioid Antagonist Market Facts & Figures by Country
3.4.1 North America Opioid Antagonist Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Opioid Antagonist Sales by Country (2020-2031)
3.4.3 North America Opioid Antagonist Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Opioid Antagonist Market Facts & Figures by Country
3.5.1 Europe Opioid Antagonist Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Opioid Antagonist Sales by Country (2020-2031)
3.5.3 Europe Opioid Antagonist Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Opioid Antagonist Market Facts & Figures by Region
3.6.1 Asia Pacific Opioid Antagonist Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Opioid Antagonist Sales by Region (2020-2031)
3.6.3 Asia Pacific Opioid Antagonist Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Opioid Antagonist Market Facts & Figures by Country
3.7.1 Latin America Opioid Antagonist Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Opioid Antagonist Sales by Country (2020-2031)
3.7.3 Latin America Opioid Antagonist Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Opioid Antagonist Market Facts & Figures by Country
3.8.1 Middle East and Africa Opioid Antagonist Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Opioid Antagonist Sales by Country (2020-2031)
3.8.3 Middle East and Africa Opioid Antagonist Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Opioid Antagonist Sales by Type (2020-2031)
4.1.1 Global Opioid Antagonist Sales by Type (2020-2025)
4.1.2 Global Opioid Antagonist Sales by Type (2026-2031)
4.1.3 Global Opioid Antagonist Sales Market Share by Type (2020-2031)
4.2 Global Opioid Antagonist Revenue by Type (2020-2031)
4.2.1 Global Opioid Antagonist Revenue by Type (2020-2025)
4.2.2 Global Opioid Antagonist Revenue by Type (2026-2031)
4.2.3 Global Opioid Antagonist Revenue Market Share by Type (2020-2031)
4.3 Global Opioid Antagonist Price by Type (2020-2031)
5 Segment by Application
5.1 Global Opioid Antagonist Sales by Application (2020-2031)
5.1.1 Global Opioid Antagonist Sales by Application (2020-2025)
5.1.2 Global Opioid Antagonist Sales by Application (2026-2031)
5.1.3 Global Opioid Antagonist Sales Market Share by Application (2020-2031)
5.2 Global Opioid Antagonist Revenue by Application (2020-2031)
5.2.1 Global Opioid Antagonist Revenue by Application (2020-2025)
5.2.2 Global Opioid Antagonist Revenue by Application (2026-2031)
5.2.3 Global Opioid Antagonist Revenue Market Share by Application (2020-2031)
5.3 Global Opioid Antagonist Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Indivior
6.1.1 Indivior Company Information
6.1.2 Indivior Description and Business Overview
6.1.3 Indivior Opioid Antagonist Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Indivior Opioid Antagonist Product Portfolio
6.1.5 Indivior Recent Developments/Updates
6.2 Alkermes
6.2.1 Alkermes Company Information
6.2.2 Alkermes Description and Business Overview
6.2.3 Alkermes Opioid Antagonist Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Alkermes Opioid Antagonist Product Portfolio
6.2.5 Alkermes Recent Developments/Updates
6.3 Titan Pharmaceuticals
6.3.1 Titan Pharmaceuticals Company Information
6.3.2 Titan Pharmaceuticals Description and Business Overview
6.3.3 Titan Pharmaceuticals Opioid Antagonist Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Titan Pharmaceuticals Opioid Antagonist Product Portfolio
6.3.5 Titan Pharmaceuticals Recent Developments/Updates
6.4 Opiant Pharmaceuticals
6.4.1 Opiant Pharmaceuticals Company Information
6.4.2 Opiant Pharmaceuticals Description and Business Overview
6.4.3 Opiant Pharmaceuticals Opioid Antagonist Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Opiant Pharmaceuticals Opioid Antagonist Product Portfolio
6.4.5 Opiant Pharmaceuticals Recent Developments/Updates
6.5 Hikma Pharmaceuticals
6.5.1 Hikma Pharmaceuticals Company Information
6.5.2 Hikma Pharmaceuticals Description and Business Overview
6.5.3 Hikma Pharmaceuticals Opioid Antagonist Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Hikma Pharmaceuticals Opioid Antagonist Product Portfolio
6.5.5 Hikma Pharmaceuticals Recent Developments/Updates
6.6 Orexo
6.6.1 Orexo Company Information
6.6.2 Orexo Description and Business Overview
6.6.3 Orexo Opioid Antagonist Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Orexo Opioid Antagonist Product Portfolio
6.6.5 Orexo Recent Developments/Updates
6.7 Camurus
6.7.1 Camurus Company Information
6.7.2 Camurus Description and Business Overview
6.7.3 Camurus Opioid Antagonist Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Camurus Opioid Antagonist Product Portfolio
6.7.5 Camurus Recent Developments/Updates
6.8 Acura Pharmaceuticals
6.8.1 Acura Pharmaceuticals Company Information
6.8.2 Acura Pharmaceuticals Description and Business Overview
6.8.3 Acura Pharmaceuticals Opioid Antagonist Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Acura Pharmaceuticals Opioid Antagonist Product Portfolio
6.8.5 Acura Pharmaceuticals Recent Developments/Updates
6.9 Shionogi
6.9.1 Shionogi Company Information
6.9.2 Shionogi Description and Business Overview
6.9.3 Shionogi Opioid Antagonist Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Shionogi Opioid Antagonist Product Portfolio
6.9.5 Shionogi Recent Developments/Updates
6.10 BioDelivery Sciences International
6.10.1 BioDelivery Sciences International Company Information
6.10.2 BioDelivery Sciences International Description and Business Overview
6.10.3 BioDelivery Sciences International Opioid Antagonist Sales, Revenue and Gross Margin (2020-2025)
6.10.4 BioDelivery Sciences International Opioid Antagonist Product Portfolio
6.10.5 BioDelivery Sciences International Recent Developments/Updates
6.11 Collegium Pharmaceutical
6.11.1 Collegium Pharmaceutical Company Information
6.11.2 Collegium Pharmaceutical Description and Business Overview
6.11.3 Collegium Pharmaceutical Opioid Antagonist Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Collegium Pharmaceutical Opioid Antagonist Product Portfolio
6.11.5 Collegium Pharmaceutical Recent Developments/Updates
6.12 AstraZeneca
6.12.1 AstraZeneca Company Information
6.12.2 AstraZeneca Description and Business Overview
6.12.3 AstraZeneca Opioid Antagonist Sales, Revenue and Gross Margin (2020-2025)
6.12.4 AstraZeneca Opioid Antagonist Product Portfolio
6.12.5 AstraZeneca Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Opioid Antagonist Industry Chain Analysis
7.2 Opioid Antagonist Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Opioid Antagonist Production Mode & Process Analysis
7.4 Opioid Antagonist Sales and Marketing
7.4.1 Opioid Antagonist Sales Channels
7.4.2 Opioid Antagonist Distributors
7.5 Opioid Antagonist Customer Analysis
8 Opioid Antagonist Market Dynamics
8.1 Opioid Antagonist Industry Trends
8.2 Opioid Antagonist Market Drivers
8.3 Opioid Antagonist Market Challenges
8.4 Opioid Antagonist Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Alkermes plc
Titan pharmaceuticals
Opiant Pharmaceuticals
Hikma Pharmaceuticals
Orexo
Camurus AB
Acura Pharmaceuticals
Shionogi
BioDelivery Sciences International
Collegium Pharmaceutical
Astrazeneca plc
List of Tables
 Table 1. Global Opioid Antagonist Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Opioid Antagonist Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Opioid Antagonist Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Opioid Antagonist Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Opioid Antagonist Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Opioid Antagonist Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Opioid Antagonist Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Opioid Antagonist Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Opioid Antagonist, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Opioid Antagonist, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Opioid Antagonist, Product Type & Application
 Table 12. Global Key Manufacturers of Opioid Antagonist, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Opioid Antagonist by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Opioid Antagonist as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Opioid Antagonist Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Opioid Antagonist Sales by Region (2020-2025) & (K Units)
 Table 18. Global Opioid Antagonist Sales Market Share by Region (2020-2025)
 Table 19. Global Opioid Antagonist Sales by Region (2026-2031) & (K Units)
 Table 20. Global Opioid Antagonist Sales Market Share by Region (2026-2031)
 Table 21. Global Opioid Antagonist Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Opioid Antagonist Revenue Market Share by Region (2020-2025)
 Table 23. Global Opioid Antagonist Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Opioid Antagonist Revenue Market Share by Region (2026-2031)
 Table 25. North America Opioid Antagonist Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Opioid Antagonist Sales by Country (2020-2025) & (K Units)
 Table 27. North America Opioid Antagonist Sales by Country (2026-2031) & (K Units)
 Table 28. North America Opioid Antagonist Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Opioid Antagonist Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Opioid Antagonist Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Opioid Antagonist Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Opioid Antagonist Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Opioid Antagonist Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Opioid Antagonist Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Opioid Antagonist Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Opioid Antagonist Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Opioid Antagonist Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Opioid Antagonist Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Opioid Antagonist Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Opioid Antagonist Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Opioid Antagonist Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Opioid Antagonist Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Opioid Antagonist Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Opioid Antagonist Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Opioid Antagonist Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Opioid Antagonist Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Opioid Antagonist Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Opioid Antagonist Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Opioid Antagonist Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Opioid Antagonist Sales (K Units) by Type (2020-2025)
 Table 51. Global Opioid Antagonist Sales (K Units) by Type (2026-2031)
 Table 52. Global Opioid Antagonist Sales Market Share by Type (2020-2025)
 Table 53. Global Opioid Antagonist Sales Market Share by Type (2026-2031)
 Table 54. Global Opioid Antagonist Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Opioid Antagonist Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Opioid Antagonist Revenue Market Share by Type (2020-2025)
 Table 57. Global Opioid Antagonist Revenue Market Share by Type (2026-2031)
 Table 58. Global Opioid Antagonist Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Opioid Antagonist Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Opioid Antagonist Sales (K Units) by Application (2020-2025)
 Table 61. Global Opioid Antagonist Sales (K Units) by Application (2026-2031)
 Table 62. Global Opioid Antagonist Sales Market Share by Application (2020-2025)
 Table 63. Global Opioid Antagonist Sales Market Share by Application (2026-2031)
 Table 64. Global Opioid Antagonist Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Opioid Antagonist Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Opioid Antagonist Revenue Market Share by Application (2020-2025)
 Table 67. Global Opioid Antagonist Revenue Market Share by Application (2026-2031)
 Table 68. Global Opioid Antagonist Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Opioid Antagonist Price (US$/Unit) by Application (2026-2031)
 Table 70. Indivior Company Information
 Table 71. Indivior Description and Business Overview
 Table 72. Indivior Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. Indivior Opioid Antagonist Product
 Table 74. Indivior Recent Developments/Updates
 Table 75. Alkermes Company Information
 Table 76. Alkermes Description and Business Overview
 Table 77. Alkermes Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Alkermes Opioid Antagonist Product
 Table 79. Alkermes Recent Developments/Updates
 Table 80. Titan Pharmaceuticals Company Information
 Table 81. Titan Pharmaceuticals Description and Business Overview
 Table 82. Titan Pharmaceuticals Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Titan Pharmaceuticals Opioid Antagonist Product
 Table 84. Titan Pharmaceuticals Recent Developments/Updates
 Table 85. Opiant Pharmaceuticals Company Information
 Table 86. Opiant Pharmaceuticals Description and Business Overview
 Table 87. Opiant Pharmaceuticals Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Opiant Pharmaceuticals Opioid Antagonist Product
 Table 89. Opiant Pharmaceuticals Recent Developments/Updates
 Table 90. Hikma Pharmaceuticals Company Information
 Table 91. Hikma Pharmaceuticals Description and Business Overview
 Table 92. Hikma Pharmaceuticals Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Hikma Pharmaceuticals Opioid Antagonist Product
 Table 94. Hikma Pharmaceuticals Recent Developments/Updates
 Table 95. Orexo Company Information
 Table 96. Orexo Description and Business Overview
 Table 97. Orexo Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Orexo Opioid Antagonist Product
 Table 99. Orexo Recent Developments/Updates
 Table 100. Camurus Company Information
 Table 101. Camurus Description and Business Overview
 Table 102. Camurus Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. Camurus Opioid Antagonist Product
 Table 104. Camurus Recent Developments/Updates
 Table 105. Acura Pharmaceuticals Company Information
 Table 106. Acura Pharmaceuticals Description and Business Overview
 Table 107. Acura Pharmaceuticals Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. Acura Pharmaceuticals Opioid Antagonist Product
 Table 109. Acura Pharmaceuticals Recent Developments/Updates
 Table 110. Shionogi Company Information
 Table 111. Shionogi Description and Business Overview
 Table 112. Shionogi Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 113. Shionogi Opioid Antagonist Product
 Table 114. Shionogi Recent Developments/Updates
 Table 115. BioDelivery Sciences International Company Information
 Table 116. BioDelivery Sciences International Description and Business Overview
 Table 117. BioDelivery Sciences International Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 118. BioDelivery Sciences International Opioid Antagonist Product
 Table 119. BioDelivery Sciences International Recent Developments/Updates
 Table 120. Collegium Pharmaceutical Company Information
 Table 121. Collegium Pharmaceutical Description and Business Overview
 Table 122. Collegium Pharmaceutical Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 123. Collegium Pharmaceutical Opioid Antagonist Product
 Table 124. Collegium Pharmaceutical Recent Developments/Updates
 Table 125. AstraZeneca Company Information
 Table 126. AstraZeneca Description and Business Overview
 Table 127. AstraZeneca Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 128. AstraZeneca Opioid Antagonist Product
 Table 129. AstraZeneca Recent Developments/Updates
 Table 130. Key Raw Materials Lists
 Table 131. Raw Materials Key Suppliers Lists
 Table 132. Opioid Antagonist Distributors List
 Table 133. Opioid Antagonist Customers List
 Table 134. Opioid Antagonist Market Trends
 Table 135. Opioid Antagonist Market Drivers
 Table 136. Opioid Antagonist Market Challenges
 Table 137. Opioid Antagonist Market Restraints
 Table 138. Research Programs/Design for This Report
 Table 139. Key Data Information from Secondary Sources
 Table 140. Key Data Information from Primary Sources
 Table 141. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Opioid Antagonist
 Figure 2. Global Opioid Antagonist Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Opioid Antagonist Market Share by Type: 2024 & 2031
 Figure 4. Oral Product Picture
 Figure 5. Parenteral Product Picture
 Figure 6. Global Opioid Antagonist Market Value by Application (2020-2031) & (US$ Million)
 Figure 7. Global Opioid Antagonist Market Share by Application: 2024 & 2031
 Figure 8. Hospitals
 Figure 9. Clinics
 Figure 10. Others
 Figure 11. Global Opioid Antagonist Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 12. Global Opioid Antagonist Market Size (2020-2031) & (US$ Million)
 Figure 13. Global Opioid Antagonist Sales (2020-2031) & (K Units)
 Figure 14. Global Opioid Antagonist Average Price (US$/Unit) & (2020-2031)
 Figure 15. Opioid Antagonist Report Years Considered
 Figure 16. Opioid Antagonist Sales Share by Manufacturers in 2024
 Figure 17. Global Opioid Antagonist Revenue Share by Manufacturers in 2024
 Figure 18. Global 5 and 10 Largest Opioid Antagonist Players: Market Share by Revenue in Opioid Antagonist in 2024
 Figure 19. Opioid Antagonist Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 20. Global Opioid Antagonist Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 21. North America Opioid Antagonist Sales Market Share by Country (2020-2031)
 Figure 22. North America Opioid Antagonist Revenue Market Share by Country (2020-2031)
 Figure 23. United States Opioid Antagonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 24. Canada Opioid Antagonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 25. Europe Opioid Antagonist Sales Market Share by Country (2020-2031)
 Figure 26. Europe Opioid Antagonist Revenue Market Share by Country (2020-2031)
 Figure 27. Germany Opioid Antagonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. France Opioid Antagonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. U.K. Opioid Antagonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Italy Opioid Antagonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Russia Opioid Antagonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Asia Pacific Opioid Antagonist Sales Market Share by Region (2020-2031)
 Figure 33. Asia Pacific Opioid Antagonist Revenue Market Share by Region (2020-2031)
 Figure 34. China Opioid Antagonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Japan Opioid Antagonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. South Korea Opioid Antagonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. India Opioid Antagonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Australia Opioid Antagonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. China Taiwan Opioid Antagonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Indonesia Opioid Antagonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Thailand Opioid Antagonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Malaysia Opioid Antagonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Latin America Opioid Antagonist Sales Market Share by Country (2020-2031)
 Figure 44. Latin America Opioid Antagonist Revenue Market Share by Country (2020-2031)
 Figure 45. Mexico Opioid Antagonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Brazil Opioid Antagonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Argentina Opioid Antagonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Middle East and Africa Opioid Antagonist Sales Market Share by Country (2020-2031)
 Figure 49. Middle East and Africa Opioid Antagonist Revenue Market Share by Country (2020-2031)
 Figure 50. Turkey Opioid Antagonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Saudi Arabia Opioid Antagonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. UAE Opioid Antagonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Global Sales Market Share of Opioid Antagonist by Type (2020-2031)
 Figure 54. Global Revenue Market Share of Opioid Antagonist by Type (2020-2031)
 Figure 55. Global Opioid Antagonist Price (US$/Unit) by Type (2020-2031)
 Figure 56. Global Sales Market Share of Opioid Antagonist by Application (2020-2031)
 Figure 57. Global Revenue Market Share of Opioid Antagonist by Application (2020-2031)
 Figure 58. Global Opioid Antagonist Price (US$/Unit) by Application (2020-2031)
 Figure 59. Opioid Antagonist Value Chain
 Figure 60. Channels of Distribution (Direct Vs Distribution)
 Figure 61. Bottom-up and Top-down Approaches for This Report
 Figure 62. Data Triangulation
 Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Leap India

SIMILAR REPORTS

Global Opioid Analgesics Market Research Report 2025
Online Opioid Addiction Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Opioid Dependence Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
OTC Oral Analgesics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Prescription Pain Relievers Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Pain Therapy Device Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Pain Relief Medications Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Alpha receptor Antagonists Market Research Report 2024
Pain Relievers Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Pain Reliever Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global OTC Painkillers Market Research Report 2024
Over the Counter OTC Analgesics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global OTC Pain Medicines Market Research Report 2024
Antidepressants Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Neck Pain Treatment Solutions Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Non opioid Pain Med Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Insomnia Medication Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Non opioid Topical Pain Relief Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Oral Analgesics Market Research Report 2024
Constrained Peptide Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

RELATED REPORTS

Global Long-Acting HIV-1 Inhibitors Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-19B19893
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Methylphenidate Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-30B3636
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Soliris Intravenous Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-3H1702
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Mouth Ulcers Drugs Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-13C3384
Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions